To explore the relevance of these in vitro findings associated with elevated EZH2 in Oct4/Sox2-expressing GSCs, we queried three distinct clinical databases and found consistently increased EZH2 expression in GBM tissue compared to non-neoplastic controls (Figure 1I). This evidence concerns the gene POU5F1 and glioblastoma.